T-cell receptor specific for Influenza Hemagglutinin peptide-MHC class I complex (HA-specific TCR) (HA-specific TCR)

The T-cell receptor (TCR) specific for Influenza Hemagglutinin (HA) peptide-MHC class I complexes is a pivotal mediator of the cellular immune response against influenza A virus (IAV). These receptors, found on CD8+ T cells, specifically recognize viral peptides—most notably the immunodominant HA 512-520 epitope—presented by Major Histocompatibility Complex (MHC) class I molecules, typically HLA-A*02:01 (PubMed: 15549131). Recognition triggers a robust cytotoxic response, including the release of granzymes and perforins to eliminate infected host cells (Janeway's Immunobiology, 2017). In biotechnology, these TCRs are leveraged as templates for TCR-engineered T-cell (TCR-T) therapies, aiming to provide broad protection against various influenza strains (Nature Reviews Drug Discovery, 2021). They also serve as critical tools for evaluating vaccine efficacy and understanding the mechanisms of T-cell exhaustion and memory formation (NCBI, 2023). However, therapeutic application is complicated by the potential for cross-reactivity with human self-antigens, which can lead to severe off-target autoimmune reactions (PubMed: 31048553). Additionally, the high mutation rate of the influenza virus can lead to epitope escape, rendering specific TCRs less effective over time. Despite these challenges, HA-specific TCRs remain a cornerstone of research into universal influenza immunity and cellular therapy design.

Other names

Influenza HA-specific TCRHA-TCRHemagglutinin-specific T-cell receptorHA-specific CD8+ T-cell receptor

Recognition of the HA peptide presented by MHC class I molecules on the surface of infected cells, triggering T-cell activation, cytokine release, and targeted lysis of the host cell.